BACKGROUND: B7-H3 exhibits altered expression in various cancers. However, the correlation between B7-H3 expression and prognosis of cancer patients remains controversial. Therefore, we elicit a meta-analysis to investigate the potential value of B7-H3 in the prognostic prediction in human cancers. MATERIALS AND METHODS: We searched PubMed (last update by June 15th, 2016) to identify studies assessing the effect of B7-H3 on survival of cancer patients. Hazard ratios (HRs) for overall survival (OS), recurrence free survival (RFS) and progression-free survival (PFS) from individual studies were calculated and pooled by using a random-effect or fix-effect model, and heterogeneity and publication bias analyses were also performed. RESULTS: Data from 24 observational studies consisting of 4141 patients were summarized. An elevated baseline B7-H3 was significantly correlated with poor OS (pooled HR = 2.09; 95% CI =1.60-2.74; P < 0.001). Differences across subgroups of tumor type (P = 0.324), year of publication (P = 0.431), ethnicity (P = 0.940), source of HR (P = 0.145), analysis type (P = 0.178) and sample size (P = 0.909) were not significant. Furthermore, high B7-H3 expression also predicted a significantly poor RFS (pooled HR = 1.39; 95% CI = 1.11-1.75; P = 0.004) but not PFS. CONCLUSIONS: This meta-analysis clarifies that elevated B7-H3 expression is significantly associated with poor survival in cancer patients.
BACKGROUND:B7-H3 exhibits altered expression in various cancers. However, the correlation between B7-H3 expression and prognosis of cancerpatients remains controversial. Therefore, we elicit a meta-analysis to investigate the potential value of B7-H3 in the prognostic prediction in humancancers. MATERIALS AND METHODS: We searched PubMed (last update by June 15th, 2016) to identify studies assessing the effect of B7-H3 on survival of cancerpatients. Hazard ratios (HRs) for overall survival (OS), recurrence free survival (RFS) and progression-free survival (PFS) from individual studies were calculated and pooled by using a random-effect or fix-effect model, and heterogeneity and publication bias analyses were also performed. RESULTS: Data from 24 observational studies consisting of 4141 patients were summarized. An elevated baseline B7-H3 was significantly correlated with poor OS (pooled HR = 2.09; 95% CI =1.60-2.74; P < 0.001). Differences across subgroups of tumor type (P = 0.324), year of publication (P = 0.431), ethnicity (P = 0.940), source of HR (P = 0.145), analysis type (P = 0.178) and sample size (P = 0.909) were not significant. Furthermore, high B7-H3 expression also predicted a significantly poor RFS (pooled HR = 1.39; 95% CI = 1.11-1.75; P = 0.004) but not PFS. CONCLUSIONS: This meta-analysis clarifies that elevated B7-H3 expression is significantly associated with poor survival in cancerpatients.
Authors: Nathan M Kendsersky; Jarrett Lindsay; E Anders Kolb; Malcolm A Smith; Beverly A Teicher; Stephen W Erickson; Eric J Earley; Yael P Mosse; Daniel Martinez; Jennifer Pogoriler; Kateryna Krytska; Khushbu Patel; David Groff; Matthew Tsang; Samson Ghilu; Yifei Wang; Steven Seaman; Yang Feng; Brad St Croix; Richard Gorlick; Raushan Kurmasheva; Peter J Houghton; John M Maris Journal: Clin Cancer Res Date: 2021-02-22 Impact factor: 12.531
Authors: Carlo Genova; Simona Boccardo; Marco Mora; Erika Rijavec; Federica Biello; Giovanni Rossi; Marco Tagliamento; Maria Giovanna Dal Bello; Simona Coco; Angela Alama; Irene Vanni; Giulia Barletta; Rita Bianchi; Claudia Maggioni; Paolo Bruzzi; Francesco Grossi Journal: J Clin Med Date: 2019-10-01 Impact factor: 4.241